Tissue Plasminogen Activator (t-PA)
- 17 October 1985
- journal article
- research article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 313 (16) , 1014-1017
- https://doi.org/10.1056/nejm198510173131609
Abstract
IN an unsigned editorial published in the Journal of the American Medical Association 25 years ago, entitled "Requirements for an Ideal Thrombolytic Agent," I concluded, "Thus, an ideal thrombolytic agent would be specific for effecting clot dissolution, adequately standardized, and capable of being given to patients without significant hazard...."1 The plasminogen activators streptokinase and urokinase, which subsequently became available for clinical use, were shown to be effective in dissolving thrombi and emboli but were not specific for fibrin. They activated plasminogen in the circulation as well as that bound to fibrin; whereas the latter action was responsible for clot dissolution, . . .Keywords
This publication has 6 references indexed in Scilit:
- The Thrombolysis in Myocardial Infarction (TIMI) TrialNew England Journal of Medicine, 1985
- RANDOMISED TRIAL OF INTRAVENOUS RECOMBINANT TISSUE-TYPE PLASMINOGEN ACTIVATOR VERSUS INTRAVENOUS STREPTOKINASE IN ACUTE MYOCARDIAL INFARCTIONThe Lancet, 1985
- A Comparative Randomized Trial of Low-Dose Versus High-Dose Streptokinase in Deep Vein Thrombosis of the ThighThrombosis and Haemostasis, 1984
- Urokinase-streptokinase embolism trial. Phase 2 results. A cooperative studyPublished by American Medical Association (AMA) ,1974
- REQUIREMENTS FOR AN IDEAL THROMBOLYTIC AGENTJAMA, 1960